Literature DB >> 19764992

Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.

Emeline de Viron1, Laurent Knoops, Thierry Connerotte, Caroline Smal, Lucienne Michaux, Pascale Saussoy, Pascal Vannuffel, Eline Beert, Marie-Christiane Vekemans, Cédric Hermans, Françoise Bontemps, Eric Van Den Neste.   

Abstract

The functional evaluation of ataxia telangiectasia mutated (ATM) and p53 was recently developed in B-cell chronic lymphocytic leukaemia (B-CLL), a disease in which the response to DNA damage is frequently altered. We identified a novel biomarker of chemosensitivity based on the induction of DNA damage by the purine nucleoside analogues (PNA) fludarabine and 2-chlorodeoxyadenosine (CdA). Using genome-wide expression profiling, it was observed that, in chemosensitive samples, PNA predominantly increased the expression of p53-dependent genes, among which PLK2 was the most highly activated at early time points. Conversely, in chemoresistant samples, p53-dependent and PLK2 responses were abolished. Using a quantitative real time polymerase chain reaction, we confirmed that PNA dose- and time-dependently increased PLK2 expression in chemosensitive but not chemoresistant B-CLL samples. Analysis of a larger cohort of B-CLL patients showed that cytotoxicity induced by PNA correlated well with PLK2 mRNA induction. Interestingly, we observed that failure to up-regulate PLK2 following PNA and chemoresistance were not strictly correlated with structural alterations in the TP53 gene. In conclusion, we propose that testing PLK2 activation after a 24-h incubation with PNA could be used to investigate the functional integrity of DNA damage-response pathways in B-CLL cells, and predict clinical sensitivity to these drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19764992     DOI: 10.1111/j.1365-2141.2009.07900.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.

Authors:  Etienne Moussay; Valérie Palissot; Laurent Vallar; Hélène A Poirel; Thomas Wenner; Victoria El Khoury; Nasséra Aouali; Kris Van Moer; Bernadette Leners; François Bernardin; Arnaud Muller; Pascale Cornillet-Lefebvre; Alain Delmer; Caroline Duhem; Fernand Ries; Eric van Dyck; Guy Berchem
Journal:  Mol Cancer       Date:  2010-05-20       Impact factor: 27.401

Review 2.  Polo-like kinases and acute leukemia.

Authors:  Oksana Goroshchuk; Iryna Kolosenko; Linda Vidarsdottir; Alireza Azimi; Caroline Palm-Apergi
Journal:  Oncogene       Date:  2018-08-13       Impact factor: 9.867

Review 3.  Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.

Authors:  Helen M Coley; Eleftheria Hatzimichael; Sarah Blagden; Iain McNeish; Alastair Thompson; Tim Crook; Nelofer Syed
Journal:  Oncotarget       Date:  2012-01

4.  Reevaluation of ATR signaling in primary resting chronic lymphocytic leukemia cells: evidence for pro-survival or pro-apoptotic function.

Authors:  Maxime Beyaert; Eliza Starczewska; Ana Cristina González Pérez; Nicolas Vanlangendonck; Pascale Saussoy; Gaëlle Tilman; Anne De Leener; Marie-Christiane Vekemans; Eric Van Den Neste; Françoise Bontemps
Journal:  Oncotarget       Date:  2017-05-24

Review 5.  Polo-Like Kinase 2: From Principle to Practice.

Authors:  Chuanyong Zhang; Chuangye Ni; Hao Lu
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

6.  P53 protein in proliferation, repair and apoptosis of cells.

Authors:  Ewelina Wawryk-Gawda; Patrycja Chylińska-Wrzos; Marta Lis-Sochocka; Katarzyna Chłapek; Kamila Bulak; Marian Jędrych; Barbara Jodłowska-Jędrych
Journal:  Protoplasma       Date:  2013-09-17       Impact factor: 3.356

7.  Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs.

Authors:  Eliza Starczewska; Maxime Beyaert; Lucienne Michaux; Marie-Christiane Vekemans; Pascale Saussoy; Vanesa Bol; Ainhoa Arana Echarri; Caroline Smal; Eric Van Den Neste; Françoise Bontemps
Journal:  Oncotarget       Date:  2016-06-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.